trial · primary record
Surzetoclax
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 325 |
| Primary completion | 2030-12 |
| Primary endpoint | Dose-Limiting Toxicities (DLT)s of ABBV-453 |
| Registry ID | NCT06953960 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:38.746Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06953960
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.